{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:28:13Z","timestamp":1793118493472,"version":"4.5.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Fondazione Roche","award":["[Call 2024_Roche per la ricerca indipendente]"],"award-info":[{"award-number":["[Call 2024_Roche per la ricerca indipendente]"]}]},{"DOI":"10.13039\/501100004271","name":"Sapienza Universit\u00e0 di Roma","doi-asserted-by":"publisher","award":["AR222181637B96CA"],"award-info":[{"award-number":["AR222181637B96CA"]}],"id":[{"id":"10.13039\/501100004271","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004271","name":"Sapienza Universit\u00e0 di Roma","doi-asserted-by":"publisher","award":["RM11916B796B4F3D"],"award-info":[{"award-number":["RM11916B796B4F3D"]}],"id":[{"id":"10.13039\/501100004271","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PRIN-2017HWTP2K"],"award-info":[{"award-number":["PRIN-2017HWTP2K"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PRIN-20223NY37M"],"award-info":[{"award-number":["PRIN-20223NY37M"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020581","name":"Fondazione AIRC per la ricerca sul cancro ETS","doi-asserted-by":"publisher","award":["IG grant 22174"],"award-info":[{"award-number":["IG grant 22174"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fondazione AIRC Special Program Molecular Clinical Oncology \u201c5 permille\u201d","award":["22759"],"award-info":[{"award-number":["22759"]}]},{"DOI":"10.13039\/501100004588","name":"Istituto Pasteur-Fondazione Cenci Bolognetti","doi-asserted-by":"publisher","award":["[Call 2020_Anna Tramontano_under 60]"],"award-info":[{"award-number":["[Call 2020_Anna Tramontano_under 60]"]}],"id":[{"id":"10.13039\/501100004588","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004588","name":"Istituto Pasteur-Fondazione Cenci Bolognetti","doi-asserted-by":"publisher","award":["[Call 2020_under 45]"],"award-info":[{"award-number":["[Call 2020_under 45]"]}],"id":[{"id":"10.13039\/501100004588","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Resistance to platinum-based drugs represents a major obstacle for the management of high-grade serous ovarian cancer (HGSOC) patients. Indeed, the selective pressure of platinum-based (PT) chemotherapy often leads to the outgrowth of platinum-resistant subclones. In this scenario, the underlying adaptive networks should be fully investigated to provide advances toward more streamlined and personalized care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a comprehensive analysis of Pin1\/Notch3relationship from HGSOC cell lines and primary tumours, integrating multiple genetic targeting under chemotherapy pressure, differential proteomic approaches, molecular docking data and dynamics simulations, thus identifying a functional circuit evaluated in vitro and in vivo models.We conducted a comprehensive analysis of relationship from HGSOC cell lines and primary tumours, integrating multiple genetic targeting under chemotherapy pressure, differential proteomic approaches, molecular docking data and dynamics simulations, thus identifying a functional circuit evaluated in vitro and in vivo models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Here, we demonstrated that carboplatin treatment of HGSOC cells promoted the activation of the Pin1\/Notch3 axis, resulting in platinum resistance. Accordingly, HGSOC-bearing patients showing increased Pin1\/Notch3 co-expression after PT-based chemotherapy correlated with a clinical worse response. Conversely, genetic targeting of Pin1 combined with carboplatin treatment sensitizes resistant cells to platinum-based therapy, both in vitro and in vivo, strongly reducing their Notch3-mediated metastatic potential in preclinical murine models. Mechanistically, Pin1-Notch3 binding favours protection of Notch3 from its GSK3\u03b2-mediated degradation, resulting in increased Notch3 expression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Collectively, our findings identify the functional Pin1\/Notch3 axis as an escape strategy from chemotherapy-induced cell death, thus suggesting a novel predictive role of the Pin1\/Notch3 axis in the platinum response, which could be useful for implementing frontline treatments for HGSOC patients before recurrence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-026-03658-x","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T23:13:09Z","timestamp":1770851589000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prolyl-isomerase Pin1 drives platinum resistance by regulating Notch3 stability and function in ovarian cancer"],"prefix":"10.1186","volume":"45","author":[{"given":"Maria Valeria","family":"Giuli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelica","family":"Mancusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Natiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuele","family":"Di Cristofano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Reali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Gemma","family":"Pignataro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"D\u2019Andrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Di Magno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Nicoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Macone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Camerini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marialuisa","family":"Casella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Peruzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Zema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Canettieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Tomao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Innocenza","family":"Palaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelina","family":"Pernazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Rustighi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocco","family":"Palermo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Raimondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Monti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nunzianna","family":"Doti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"d\u2019Amati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giannino","family":"Del Sal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Screpanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Talora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Bellavia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saula","family":"Checquolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"issue":"1","key":"3658_CR1","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13048-022-01004-1","volume":"15","author":"P Achimas-Cadariu","year":"2022","unstructured":"Achimas-Cadariu P, Kubelac P, Irimie A, Berindan-Neagoe I, R\u00fchli F. Evolutionary perspectives, heterogeneity and ovarian cancer: a complicated Tale from past to present. J Ovarian Res. 2022;15(1):67.","journal-title":"J Ovarian Res"},{"issue":"1","key":"3658_CR2","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1097\/AOG.0000000000004173","volume":"137","author":"KC Kurnit","year":"2021","unstructured":"Kurnit KC, Fleming GF, Lengyel E. Updates and new options in advanced epithelial ovarian cancer treatment. Obstet Gynecol. 2021;137(1):108\u201321.","journal-title":"Obstet Gynecol"},{"issue":"24","key":"3658_CR3","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.21037\/atm-20-1683","volume":"8","author":"M Moschetta","year":"2020","unstructured":"Moschetta M, Boussios S, Rassy E, Samartzis EP, Funingana G, Uccello M. Neoadjuvant treatment for newly diagnosed advanced ovarian cancer: where do we stand and where are we going? Ann Transl Med. 2020;8(24):1710\u20131710.","journal-title":"Ann Transl Med"},{"issue":"16","key":"3658_CR4","doi-asserted-by":"publisher","first-page":"7018","DOI":"10.1002\/cam4.2560","volume":"8","author":"A Chandra","year":"2019","unstructured":"Chandra A, Pius C, Nabeel M, Nair M, Vishwanatha JK, Ahmad S, et al. Ovarian cancer: current status and strategies for improving therapeutic outcomes. Cancer Med. 2019;8(16):7018\u201331.","journal-title":"Cancer Med"},{"issue":"1","key":"3658_CR5","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3390\/curroncol31010015","volume":"31","author":"J Wilczy\u0144ski","year":"2023","unstructured":"Wilczy\u0144ski J, Paradowska E, Wilczy\u0144ska J, Wilczy\u0144ski M. Prediction of Chemoresistance\u2014How preclinical data could help to modify therapeutic strategy in High-Grade serous ovarian cancer. Curr Oncol. 2023;31(1):229\u201349.","journal-title":"Curr Oncol"},{"issue":"1","key":"3658_CR6","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3390\/cells10010094","volume":"10","author":"JO Misiorek","year":"2021","unstructured":"Misiorek JO, Przybyszewska-Podstawka A, Ka\u0142afut J, Paziewska B, Rolle K, Rivero-M\u00fcller A, et al. Context matters: NOTCH signatures and pathway in cancer progression and metastasis. Cells. 2021;10(1):94.","journal-title":"Cells"},{"key":"3658_CR7","doi-asserted-by":"crossref","unstructured":"Orzechowska M, Anusewicz D, Bednarek AK. Functional gene expression differentiation of the Notch signaling pathway in female reproductive tract Tissues\u2014A comprehensive review with analysis. Front Cell Dev Biol. 2020;8:592616 .","DOI":"10.3389\/fcell.2020.592616"},{"issue":"11","key":"3658_CR8","doi-asserted-by":"publisher","first-page":"153158","DOI":"10.1016\/j.prp.2020.153158","volume":"216","author":"M Akbarzadeh","year":"2020","unstructured":"Akbarzadeh M, Akbarzadeh S, Majidinia M. Targeting Notch signaling pathway as an effective strategy in overcoming drug resistance in ovarian cancer. Pathol Res Pract. 2020;216(11):153158.","journal-title":"Pathol Res Pract"},{"key":"3658_CR9","doi-asserted-by":"crossref","unstructured":"Giuli MV, Mancusi A, Giuliani E, Screpanti I, Checquolo S. Notch signaling in female cancers: a multifaceted node to overcome drug resistance. Cancer Drug Resist. 2021;4(4):805-836.","DOI":"10.20517\/cdr.2021.53"},{"issue":"12","key":"3658_CR10","doi-asserted-by":"publisher","first-page":"6312","DOI":"10.1158\/0008-5472.CAN-05-3610","volume":"66","author":"JT Park","year":"2006","unstructured":"Park JT, Li M, Nakayama K, Mao TL, Davidson B, Zhang Z, et al. Notch3 gene amplification in ovarian cancer. Cancer Res. 2006;66(12):6312\u20138.","journal-title":"Cancer Res"},{"key":"3658_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/6264931","volume":"2019","author":"S Ceccarelli","year":"2019","unstructured":"Ceccarelli S, Megiorni F, Bellavia D, Marchese C, Screpanti I, Checquolo S. Notch3 targeting: A novel weapon against ovarian cancer stem cells. Stem Cells Int. 2019;2019:1\u20138.","journal-title":"Stem Cells Int"},{"issue":"1","key":"3658_CR12","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12967-019-1942-z","volume":"17","author":"J Hoarau-V\u00e9chot","year":"2019","unstructured":"Hoarau-V\u00e9chot J, Touboul C, Halabi N, Blot-Dupin M, Lis R, Abi Khalil C, et al. Akt-activated endothelium promotes ovarian cancer proliferation through Notch activation. J Transl Med. 2019;17(1):194.","journal-title":"J Transl Med"},{"issue":"1","key":"3658_CR13","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1002\/cam4.1812","volume":"8","author":"Y Xu","year":"2019","unstructured":"Xu Y, Zhang Q, Miao C, Dongol S, Li Y, Jin C, et al. CCNG1 (Cyclin G1) regulation by mutant-P53 via induction of Notch3 expression promotes high\u2010grade serous ovarian cancer (HGSOC) tumorigenesis and progression. Cancer Med. 2019;8(1):351\u201362.","journal-title":"Cancer Med"},{"issue":"5","key":"3658_CR14","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1158\/0008-5472.CAN-06-3958","volume":"67","author":"IM Shih","year":"2007","unstructured":"Shih IM, Wang TL. Notch signaling, gamma-secretase inhibitors, and cancer therapy. Cancer Res. 2007;67(5):1879\u201382.","journal-title":"Cancer Res"},{"issue":"1","key":"3658_CR15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41392-022-00934-y","volume":"7","author":"B Zhou","year":"2022","unstructured":"Zhou B, Lin W, Long Y, Yang Y, Zhang H, Wu K, et al. Notch signaling pathway: architecture, disease, and therapeutics. Signal Transduct Target Ther. 2022;7(1):95.","journal-title":"Signal Transduct Target Ther"},{"key":"3658_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2018.04.055","volume":"281","author":"C Russo Spena","year":"2018","unstructured":"Russo Spena C, De Stefano L, Palazzolo S, Salis B, Granchi C, Minutolo F, et al. Liposomal delivery of a Pin1 inhibitor complexed with cyclodextrins as new therapy for high-grade serous ovarian cancer. J Controlled Release. 2018;281:1\u201310.","journal-title":"J Controlled Release"},{"key":"3658_CR17","doi-asserted-by":"publisher","first-page":"106456","DOI":"10.1016\/j.phrs.2022.106456","volume":"184","author":"W Wu","year":"2022","unstructured":"Wu W, Xue X, Chen Y, Zheng N, Wang J. Targeting Prolyl isomerase Pin1 as a promising strategy to overcome resistance to cancer therapies. Pharmacol Res. 2022;184:106456.","journal-title":"Pharmacol Res"},{"issue":"1","key":"3658_CR18","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/emmm.201302909","volume":"6","author":"A Rustighi","year":"2014","unstructured":"Rustighi A, Zannini A, Tiberi L, Sommaggio R, Piazza S, Sorrentino G, et al. Prolyl-isomerase Pin1 controls normal and cancer stem cells of the breast. EMBO Mol Med. 2014;6(1):99\u2013119.","journal-title":"EMBO Mol Med"},{"issue":"36","key":"3658_CR19","doi-asserted-by":"publisher","first-page":"4741","DOI":"10.1038\/onc.2016.5","volume":"35","author":"G Franciosa","year":"2016","unstructured":"Franciosa G, Diluvio G, Gaudio F, Del, Giuli MV, Palermo R, Grazioli P, et al. Prolyl-isomerase Pin1 controls Notch3 protein expression and regulates T-ALL progression. Oncogene. 2016;35(36):4741\u201351.","journal-title":"Oncogene"},{"issue":"1","key":"3658_CR20","doi-asserted-by":"publisher","first-page":"15772","DOI":"10.1038\/ncomms15772","volume":"8","author":"E Campaner","year":"2017","unstructured":"Campaner E, Rustighi A, Zannini A, Cristiani A, Piazza S, Ciani Y, et al. A covalent PIN1 inhibitor selectively targets cancer cells by a dual mechanism of action. Nat Commun. 2017;8(1):15772.","journal-title":"Nat Commun"},{"issue":"2","key":"3658_CR21","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/ncb1822","volume":"11","author":"A Rustighi","year":"2009","unstructured":"Rustighi A, Tiberi L, Soldano A, Napoli M, Nuciforo P, Rosato A, et al. The prolyl-isomerase Pin1 is a Notch1 target that enhances Notch1 activation in cancer. Nat Cell Biol. 2009;11(2):133\u201342.","journal-title":"Nat Cell Biol"},{"key":"3658_CR22","doi-asserted-by":"crossref","unstructured":"Yan XD, Li M, Yuan Y, Mao N, Pan LY. Biological comparison of ovarian cancer resistant cell lines to cisplatin and taxol by two different administrations. Oncol Rep. 2007;17(5):1163-9 .","DOI":"10.3892\/or.17.5.1163"},{"issue":"10","key":"3658_CR23","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.15252\/emmm.201607012","volume":"9","author":"A Dall\u2019Acqua","year":"2017","unstructured":"Dall\u2019Acqua A, Sonego M, Pellizzari I, Pellarin I, Canzonieri V, D\u2019Andrea S, et al. CDK6 protects epithelial ovarian cancer from platinum-induced death via FOXO3 regulation. EMBO Mol Med. 2017;9(10):1415\u201333.","journal-title":"EMBO Mol Med"},{"key":"3658_CR24","doi-asserted-by":"crossref","unstructured":"Tottone L, Zhdanovskaya N, Carmona Pesta\u00f1a \u00c1, Zampieri M, Simeoni F, Lazzari S et al. Histone modifications drive aberrant Notch3 Expression\/Activity and growth in T-ALL. Front Oncol. 2019;9:198.","DOI":"10.3389\/fonc.2019.00198"},{"issue":"21","key":"3658_CR25","doi-asserted-by":"publisher","first-page":"5575","DOI":"10.1158\/0008-5472.CAN-19-0145","volume":"79","author":"M Pelullo","year":"2019","unstructured":"Pelullo M, Nardozza F, Zema S, Quaranta R, Nicoletti C, Besharat ZM, et al. Kras\/ADAM17-Dependent Jag1-ICD reverse signaling sustains colorectal cancer progression and chemoresistance. Cancer Res. 2019;79(21):5575\u201386.","journal-title":"Cancer Res"},{"issue":"3","key":"3658_CR26","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.cell.2016.05.069","volume":"166","author":"H Zhang","year":"2016","unstructured":"Zhang H, Liu T, Zhang Z, Payne SH, Zhang B, McDermott JE, et al. Integrated proteogenomic characterization of human High-Grade serous ovarian cancer. Cell. 2016;166(3):755\u201365.","journal-title":"Cell"},{"key":"3658_CR27","doi-asserted-by":"crossref","unstructured":"Sueblinvong T, Ghebre R, Iizuka Y, Pambuccian SE, Isaksson Vogel R, Skubitz APN et al. Establishment, characterization and downstream application of primary ovarian cancer cells derived from solid tumors. PLoS ONE. 2012;7(11):e50519.","DOI":"10.1371\/journal.pone.0050519"},{"issue":"10","key":"3658_CR28","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41389-020-00279-7","volume":"9","author":"MV Giuli","year":"2020","unstructured":"Giuli MV, Diluvio G, Giuliani E, Franciosa G, Di Magno L, Pignataro MG, et al. Notch3 contributes to T-cell leukemia growth via regulation of the unfolded protein response. Oncogenesis. 2020;9(10):93.","journal-title":"Oncogenesis"},{"issue":"2","key":"3658_CR29","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.ygyno.2016.05.028","volume":"142","author":"L Hernandez","year":"2016","unstructured":"Hernandez L, Kim MK, Lyle LT, Bunch KP, House CD, Ning F, et al. Characterization of ovarian cancer cell lines as in vivo models for preclinical studies. Gynecol Oncol. 2016;142(2):332\u201340.","journal-title":"Gynecol Oncol"},{"key":"3658_CR30","doi-asserted-by":"crossref","unstructured":"McAuliffe SM, Morgan SL, Wyant GA, Tran LT, Muto KW, Chen YS et al. Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proceedings of the National Academy of Sciences. 2012;109(43):E2939-48 .","DOI":"10.1073\/pnas.1206400109"},{"issue":"1","key":"3658_CR31","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s10555-013-9456-2","volume":"33","author":"B Thibault","year":"2014","unstructured":"Thibault B, Castells M, Delord JP, Couderc B. Ovarian cancer microenvironment: implications for cancer dissemination and chemoresistance acquisition. Cancer Metastasis Rev. 2014;33(1):17\u201339.","journal-title":"Cancer Metastasis Rev"},{"issue":"1","key":"3658_CR32","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1038\/ncomms3126","volume":"4","author":"S Domcke","year":"2013","unstructured":"Domcke S, Sinha R, Levine DA, Sander C, Schultz N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun. 2013;4(1):2126.","journal-title":"Nat Commun"},{"issue":"46","key":"3658_CR33","doi-asserted-by":"publisher","first-page":"6395","DOI":"10.1038\/s41388-021-02055-2","volume":"40","author":"D Huang","year":"2021","unstructured":"Huang D, Savage SR, Calinawan AP, Lin C, Zhang B, Wang P, et al. A highly annotated database of genes associated with platinum resistance in cancer. Oncogene. 2021;40(46):6395\u2013405.","journal-title":"Oncogene"},{"issue":"6574","key":"3658_CR34","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/380544a0","volume":"380","author":"K Ping Lu","year":"1996","unstructured":"Ping Lu K, Hanes SD, Hunter T. A human peptidyl\u2013prolyl isomerase essential for regulation of mitosis. Nature. 1996;380(6574):544\u20137.","journal-title":"Nature"},{"issue":"12","key":"3658_CR35","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1074\/mcp.TIR120.002129","volume":"19","author":"D Samodova","year":"2020","unstructured":"Samodova D, Hosfield CM, Cramer CN, Giuli MV, Cappellini E, Franciosa G, et al. ProAlanase is an effective alternative to trypsin for proteomics applications and disulfide bond mapping. Mol Cell Proteom. 2020;19(12):2139\u201357.","journal-title":"Mol Cell Proteom"},{"issue":"2","key":"3658_CR36","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ab.2008.03.035","volume":"377","author":"Y Abdiche","year":"2008","unstructured":"Abdiche Y, Malashock D, Pinkerton A, Pons J. Determining kinetics and affinities of protein interactions using a parallel real-time label-free biosensor, the octet. Anal Biochem. 2008;377(2):209\u201317.","journal-title":"Anal Biochem"},{"key":"3658_CR37","doi-asserted-by":"crossref","unstructured":"Passaro S, Corso G, Wohlwend J, Reveiz M, Thaler S, Somnath VR, et al. Boltz-2. Towards Accurate and Efficient Binding Affinity Prediction; 2025.","DOI":"10.1101\/2025.06.14.659707"},{"issue":"D1","key":"3658_CR38","doi-asserted-by":"publisher","first-page":"D428","DOI":"10.1093\/nar\/gkx1077","volume":"46","author":"M Gouw","year":"2018","unstructured":"Gouw M, Michael S, S\u00e1mano-S\u00e1nchez H, Kumar M, Zeke A, Lang B, et al. The eukaryotic linear motif resource \u2013 2018 update. Nucleic Acids Res. 2018;46(D1):D428\u201334.","journal-title":"Nucleic Acids Res"},{"issue":"24","key":"3658_CR39","doi-asserted-by":"publisher","first-page":"4032","DOI":"10.4161\/cc.8.24.10111","volume":"8","author":"C Xu","year":"2009","unstructured":"Xu C, Kim NG, Gumbiner BM. Regulation of protein stability by GSK3 mediated phosphorylation. Cell Cycle. 2009;8(24):4032\u20139.","journal-title":"Cell Cycle"},{"issue":"4","key":"3658_CR40","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1093\/annonc\/mdw663","volume":"28","author":"MK Wilson","year":"2017","unstructured":"Wilson MK, Pujade-Lauraine E, Aoki D, Mirza MR, Lorusso D, Oza AM, et al. Fifth ovarian cancer consensus conference of the gynecologic cancer intergroup: recurrent disease. Ann Oncol. 2017;28(4):727\u201332.","journal-title":"Ann Oncol"},{"issue":"12","key":"3658_CR41","first-page":"118507","volume":"1866","author":"D Antfolk","year":"2019","unstructured":"Antfolk D, Antila C, Kemppainen K, Landor SKJ, Sahlgren C. Decoding the PTM-switchboard of Notch. Biochimica et biophysica acta (BBA) -. Mol Cell Res. 2019;1866(12):118507.","journal-title":"Mol Cell Res"},{"issue":"10","key":"3658_CR42","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.4161\/cc.10.10.15630","volume":"10","author":"ND Kashikar","year":"2011","unstructured":"Kashikar ND, Zhang W, Massion PP, Gonzalez AL, Datta PK. Role of STRAP in regulating GSK3\u03b2 function and Notch3 stabilization. Cell Cycle. 2011;10(10):1639\u201354.","journal-title":"Cell Cycle"},{"issue":"5","key":"3658_CR43","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s00432-010-0934-4","volume":"137","author":"C Li","year":"2011","unstructured":"Li C, Zhang Y, Lu Y, Cui Z, Yu M, Zhang S, et al. Evidence of the cross talk between Wnt and Notch signaling pathways in non-small-cell lung cancer (NSCLC): Notch3-siRNA weakens the effect of LiCl on the cell cycle of NSCLC cell lines. J Cancer Res Clin Oncol. 2011;137(5):771\u20138.","journal-title":"J Cancer Res Clin Oncol"},{"key":"3658_CR44","doi-asserted-by":"crossref","unstructured":"Glibo M, Serman A, Karin-Kujundzic V, Bekavac Vlatkovic I, Miskovic B, Vranic S et al. The role of glycogen synthase kinase 3 (GSK3) in cancer with emphasis on ovarian cancer development and progression: A comprehensive review. Bosn J Basic Med Sci. 2020;21(1):5-18 .","DOI":"10.17305\/bjbms.2020.5036"},{"key":"3658_CR45","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.semcancer.2019.05.012","volume":"59","author":"MK Ediriweera","year":"2019","unstructured":"Ediriweera MK, Tennekoon KH, Samarakoon SR. Role of the PI3K\/AKT\/mTOR signaling pathway in ovarian cancer: biological and therapeutic significance. Semin Cancer Biol. 2019;59:147\u201360.","journal-title":"Semin Cancer Biol"},{"issue":"6","key":"3658_CR46","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.3892\/or.2020.7817","volume":"44","author":"R He","year":"2020","unstructured":"He R, Du S, Lei T, Xie X, Wang Y. Glycogen synthase kinase 3\u03b2 in tumorigenesis and oncotherapy (Review). Oncol Rep. 2020;44(6):2373\u201385.","journal-title":"Oncol Rep"},{"issue":"3","key":"3658_CR47","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.2353\/ajpath.2010.100316","volume":"177","author":"JT Park","year":"2010","unstructured":"Park JT, Chen X, Trop\u00e8 CG, Davidson B, Shih IM, Wang TL. Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin. Am J Pathol. 2010;177(3):1087\u201394.","journal-title":"Am J Pathol"},{"key":"3658_CR48","doi-asserted-by":"crossref","unstructured":"Chinchalongporn V, Shukla M, Govitrapong P. Melatonin ameliorates A\u03b2 42 -induced alteration of \u03b2\u2009<\u2009scp\u2009>\u2009APP \u2010processing secretases via the melatonin receptor through the Pin1\/ GSK 3\u03b2\/ NF \u2010\u03baB pathway in <\u2009scp>SH \u2010 SY 5Y cells. J Pineal Res. 2018;64(4):e12470 .","DOI":"10.1111\/jpi.12470"},{"key":"3658_CR49","doi-asserted-by":"publisher","first-page":"110599","DOI":"10.1016\/j.intimp.2023.110599","volume":"123","author":"J Yuan","year":"2023","unstructured":"Yuan J, Li S, Han Y, Li F, Shi H, Shi W, et al. Restoration of miR-328a-5p function curtails hypoxic pulmonary hypertension through a mechanism involving PIN1\/GSK3\u03b2\/\u03b2-catenin axis. Int Immunopharmacol. 2023;123:110599.","journal-title":"Int Immunopharmacol"},{"issue":"24","key":"3658_CR50","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.21037\/atm-20-4497","volume":"8","author":"JA Perez-Fidalgo","year":"2020","unstructured":"Perez-Fidalgo JA, Ortega B, Simon S, Samartzis EP, Boussios S. NOTCH signalling in ovarian cancer angiogenesis. Ann Transl Med. 2020;8(24):1705\u20131705.","journal-title":"Ann Transl Med"},{"issue":"14","key":"3658_CR51","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1158\/0008-5472.CAN-19-2739","volume":"80","author":"ML Luo","year":"2020","unstructured":"Luo ML, Zheng F, Chen W, Liang ZM, Chandramouly G, Tan J, et al. Inactivation of the Prolyl isomerase Pin1 sensitizes BRCA1-Proficient breast cancer to PARP Inhibition. Cancer Res. 2020;80(14):3033\u201345.","journal-title":"Cancer Res"},{"issue":"4","key":"3658_CR52","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1136\/ijgc-2022-004149","volume":"33","author":"G Caruso","year":"2023","unstructured":"Caruso G, Tomao F, Parma G, Lapresa M, Multinu F, Palaia I, et al. Poly (ADP-ribose) polymerase inhibitors (PARPi) in ovarian cancer: lessons learned and future directions. Int J Gynecologic Cancer. 2023;33(4):431\u201343.","journal-title":"Int J Gynecologic Cancer"},{"issue":"3","key":"3658_CR53","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1006\/bbrc.1999.1736","volume":"265","author":"F Fujimori","year":"1999","unstructured":"Fujimori F, Takahashi K, Uchida C, Uchida T. Mice lacking Pin1 develop Normally, but are defective in entering cell cycle from G0 arrest. Biochem Biophys Res Commun. 1999;265(3):658\u201363.","journal-title":"Biochem Biophys Res Commun"},{"issue":"9","key":"3658_CR54","doi-asserted-by":"publisher","first-page":"15708","DOI":"10.1002\/jcp.28224","volume":"234","author":"C Russo Spena","year":"2019","unstructured":"Russo Spena C, De Stefano L, Poli G, Granchi C, El Boustani M, Ecca F, et al. Virtual screening identifies a PIN1 inhibitor with possible antiovarian cancer effects. J Cell Physiol. 2019;234(9):15708\u201316.","journal-title":"J Cell Physiol"},{"key":"3658_CR55","doi-asserted-by":"publisher","first-page":"107171","DOI":"10.1016\/j.bioorg.2024.107171","volume":"144","author":"Y Bai","year":"2024","unstructured":"Bai Y, Yuan Z, Yuan S, He Z. Recent advances of Pin1 inhibitors as potential anticancer agents. Bioorg Chem. 2024;144:107171.","journal-title":"Bioorg Chem"},{"issue":"5","key":"3658_CR56","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nm.3839","volume":"21","author":"S Wei","year":"2015","unstructured":"Wei S, Kozono S, Kats L, Nechama M, Li W, Guarnerio J, et al. Active Pin1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancer. Nat Med. 2015;21(5):457\u201366.","journal-title":"Nat Med"},{"issue":"6","key":"3658_CR57","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/s41408-021-00514-3","volume":"11","author":"M Yilmaz","year":"2021","unstructured":"Yilmaz M, Kantarjian H, Ravandi F. Acute promyelocytic leukemia current treatment algorithms. Blood Cancer J. 2021;11(6):123.","journal-title":"Blood Cancer J"},{"issue":"2","key":"3658_CR58","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3390\/jcm9020360","volume":"9","author":"L Costantini","year":"2020","unstructured":"Costantini L, Molinari R, Farinon B, Merendino N. Retinoic acids in the treatment of most lethal solid cancers. J Clin Med. 2020;9(2):360.","journal-title":"J Clin Med"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-026-03658-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03658-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03658-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T12:06:32Z","timestamp":1773835592000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-026-03658-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3658"],"URL":"https:\/\/doi.org\/10.1186\/s13046-026-03658-x","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"assertion":[{"value":"8 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The human study was approved by the ethical Committee of the Policlinico Umberto I (Rome, Italy) (n\u00b00067\/2024). Informed consent was obtained from all the subjects, and the experiments conformed to the principles set out in the WMA Declaration of Helsinki and the Department of Health and Human Services Belmont Report. For the institutional tissue bank, all patients had previously provided written informed consent indicating their authorization or refusal for the collection, storage, and research use of biological and tissue samples. All animal protocols were approved by local ethics authorities (Italian Ministry of University and Research Authorization n.199\/2019-PR - PI: Saula Checquolo) and conducted in accordance with Italian Governing Law (D.lgs 26\/2014). We followed the European and national regulations for the care and use of animals to protect them for experimental and other scientific purposes (D.lgs 26\/2014).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"71"}}